Eikon Therapeutics, Inc. Common Stock (EIKN) vs NeoGenomics, Inc. (NEO)

A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Eikon Therapeutics, Inc. Common Stock logo
EIKN
Eikon Therapeutics, Inc. Common Stock
$416M
$7.68HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
NeoGenomics, Inc. logo
NEO
NeoGenomics, Inc.
$432M
$16.80HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT

Total return — EIKN vs NEO

growth of $100 · dividends reinvested · last 1y
EIKN -49.7% (-49.7%/yr)NEO +69.7% (+69.7%/yr)NEO compounded faster over this window
50100150Start $100$50$170
EIKN NEO

EIKN vs NEO: by the numbers

  • •NEO is the larger company ($432M vs $416M market cap).
  • •Both run net losses; EIKN's is the smaller (0.00% vs -6.77% net margin).

Metrics side by side

Valuation

MetricEIKNNEO
Forward P/EN/A91.97
P/S ratioN/A0.56
P/B ratio0.890.55

Profitability

MetricEIKNNEO
Gross margin0.00%42.92%
Operating margin0.00%-8.63%
Net margin0.00%-6.77%
ROE-69.06%-6.60%
ROIC-46.16%-5.29%

Growth (annualized)

MetricEIKNNEO
Revenue CAGR (5Y)N/A9.41%
Total return CAGR (5Y)N/A-15.14%

Go deeper

Full EIKN analysisFull NEO analysisInteractive comparison tool

Dig into the metrics

Eikon Therapeutics, Inc. Common Stock ROENeoGenomics ROEEikon Therapeutics, Inc. Common Stock operating marginNeoGenomics operating marginEikon Therapeutics, Inc. Common Stock revenue growthNeoGenomics revenue growthEikon Therapeutics, Inc. Common Stock free cash flowNeoGenomics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.